Genotype and phenotype variability in Sjögren-Larsson syndrome

Maximilian Weustenfeld, Reiner Eidelpes, Matthias Schmuth, William B Rizzo, Johannes Zschocke, Markus A. Keller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The Sjögren–Larsson syndrome (SLS) is a rare autosomal recessive disorder caused by pathogenic variants in the ALDH3A2 gene, which codes for fatty aldehyde dehydrogenase (FALDH). FALDH prevents the accumulation of toxic fatty aldehydes by converting them into fatty acids. Pathogenic ALDH3A2 variants cause symptoms such as ichthyosis, spasticity, intellectual disability, and a wide range of less common clinical features. Interpreting patient-to-patient variability is often complicated by inconsistent reporting and negatively impacts on establishing robust criteria to measure the success of SLS treatments. Thus, with this study, patient-centered literature data was merged into a concise genotype-based, open-access database (www.LOVD.nl/ALDH3A2). One hundred and seventy eight individuals with 90 unique SLS-causing variants were included with phenotypic data being available for more than 90%. While the three lead symptoms did occur in almost all cases, more heterogeneity was observed for other frequent clinical manifestations of SLS. However, a stringent genotype–phenotype correlation analysis was hampered by the considerable variability in reporting phenotypic features. Consequently, we compiled a set of recommendations of how to generate comprehensive SLS patient descriptions in the future. This will be of benefit on multiple levels, for example, in clinical diagnosis, basic research, and the development of novel treatment options for SLS.

Original languageEnglish (US)
Pages (from-to)177-186
Number of pages10
JournalHuman mutation
Volume40
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

long-chain-aldehyde dehydrogenase
Genotype
Phenotype
Ichthyosis
Poisons
Intellectual Disability
Fatty Acids
Databases
Therapeutics
Research
Genes

Keywords

  • ALDH3A2
  • FALDH
  • SLS
  • Sjögren–Larsson syndrome
  • database
  • fatty aldehyde dehydrogenase

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Weustenfeld, M., Eidelpes, R., Schmuth, M., Rizzo, W. B., Zschocke, J., & Keller, M. A. (2019). Genotype and phenotype variability in Sjögren-Larsson syndrome. Human mutation, 40(2), 177-186. https://doi.org/10.1002/humu.23679

Genotype and phenotype variability in Sjögren-Larsson syndrome. / Weustenfeld, Maximilian; Eidelpes, Reiner; Schmuth, Matthias; Rizzo, William B; Zschocke, Johannes; Keller, Markus A.

In: Human mutation, Vol. 40, No. 2, 01.02.2019, p. 177-186.

Research output: Contribution to journalArticle

Weustenfeld, M, Eidelpes, R, Schmuth, M, Rizzo, WB, Zschocke, J & Keller, MA 2019, 'Genotype and phenotype variability in Sjögren-Larsson syndrome', Human mutation, vol. 40, no. 2, pp. 177-186. https://doi.org/10.1002/humu.23679
Weustenfeld M, Eidelpes R, Schmuth M, Rizzo WB, Zschocke J, Keller MA. Genotype and phenotype variability in Sjögren-Larsson syndrome. Human mutation. 2019 Feb 1;40(2):177-186. https://doi.org/10.1002/humu.23679
Weustenfeld, Maximilian ; Eidelpes, Reiner ; Schmuth, Matthias ; Rizzo, William B ; Zschocke, Johannes ; Keller, Markus A. / Genotype and phenotype variability in Sjögren-Larsson syndrome. In: Human mutation. 2019 ; Vol. 40, No. 2. pp. 177-186.
@article{b66b9635a2244da79cfc89eeb13b39bd,
title = "Genotype and phenotype variability in Sj{\"o}gren-Larsson syndrome",
abstract = "The Sj{\"o}gren–Larsson syndrome (SLS) is a rare autosomal recessive disorder caused by pathogenic variants in the ALDH3A2 gene, which codes for fatty aldehyde dehydrogenase (FALDH). FALDH prevents the accumulation of toxic fatty aldehydes by converting them into fatty acids. Pathogenic ALDH3A2 variants cause symptoms such as ichthyosis, spasticity, intellectual disability, and a wide range of less common clinical features. Interpreting patient-to-patient variability is often complicated by inconsistent reporting and negatively impacts on establishing robust criteria to measure the success of SLS treatments. Thus, with this study, patient-centered literature data was merged into a concise genotype-based, open-access database (www.LOVD.nl/ALDH3A2). One hundred and seventy eight individuals with 90 unique SLS-causing variants were included with phenotypic data being available for more than 90{\%}. While the three lead symptoms did occur in almost all cases, more heterogeneity was observed for other frequent clinical manifestations of SLS. However, a stringent genotype–phenotype correlation analysis was hampered by the considerable variability in reporting phenotypic features. Consequently, we compiled a set of recommendations of how to generate comprehensive SLS patient descriptions in the future. This will be of benefit on multiple levels, for example, in clinical diagnosis, basic research, and the development of novel treatment options for SLS.",
keywords = "ALDH3A2, FALDH, SLS, Sj{\"o}gren–Larsson syndrome, database, fatty aldehyde dehydrogenase",
author = "Maximilian Weustenfeld and Reiner Eidelpes and Matthias Schmuth and Rizzo, {William B} and Johannes Zschocke and Keller, {Markus A.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/humu.23679",
language = "English (US)",
volume = "40",
pages = "177--186",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Genotype and phenotype variability in Sjögren-Larsson syndrome

AU - Weustenfeld, Maximilian

AU - Eidelpes, Reiner

AU - Schmuth, Matthias

AU - Rizzo, William B

AU - Zschocke, Johannes

AU - Keller, Markus A.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The Sjögren–Larsson syndrome (SLS) is a rare autosomal recessive disorder caused by pathogenic variants in the ALDH3A2 gene, which codes for fatty aldehyde dehydrogenase (FALDH). FALDH prevents the accumulation of toxic fatty aldehydes by converting them into fatty acids. Pathogenic ALDH3A2 variants cause symptoms such as ichthyosis, spasticity, intellectual disability, and a wide range of less common clinical features. Interpreting patient-to-patient variability is often complicated by inconsistent reporting and negatively impacts on establishing robust criteria to measure the success of SLS treatments. Thus, with this study, patient-centered literature data was merged into a concise genotype-based, open-access database (www.LOVD.nl/ALDH3A2). One hundred and seventy eight individuals with 90 unique SLS-causing variants were included with phenotypic data being available for more than 90%. While the three lead symptoms did occur in almost all cases, more heterogeneity was observed for other frequent clinical manifestations of SLS. However, a stringent genotype–phenotype correlation analysis was hampered by the considerable variability in reporting phenotypic features. Consequently, we compiled a set of recommendations of how to generate comprehensive SLS patient descriptions in the future. This will be of benefit on multiple levels, for example, in clinical diagnosis, basic research, and the development of novel treatment options for SLS.

AB - The Sjögren–Larsson syndrome (SLS) is a rare autosomal recessive disorder caused by pathogenic variants in the ALDH3A2 gene, which codes for fatty aldehyde dehydrogenase (FALDH). FALDH prevents the accumulation of toxic fatty aldehydes by converting them into fatty acids. Pathogenic ALDH3A2 variants cause symptoms such as ichthyosis, spasticity, intellectual disability, and a wide range of less common clinical features. Interpreting patient-to-patient variability is often complicated by inconsistent reporting and negatively impacts on establishing robust criteria to measure the success of SLS treatments. Thus, with this study, patient-centered literature data was merged into a concise genotype-based, open-access database (www.LOVD.nl/ALDH3A2). One hundred and seventy eight individuals with 90 unique SLS-causing variants were included with phenotypic data being available for more than 90%. While the three lead symptoms did occur in almost all cases, more heterogeneity was observed for other frequent clinical manifestations of SLS. However, a stringent genotype–phenotype correlation analysis was hampered by the considerable variability in reporting phenotypic features. Consequently, we compiled a set of recommendations of how to generate comprehensive SLS patient descriptions in the future. This will be of benefit on multiple levels, for example, in clinical diagnosis, basic research, and the development of novel treatment options for SLS.

KW - ALDH3A2

KW - FALDH

KW - SLS

KW - Sjögren–Larsson syndrome

KW - database

KW - fatty aldehyde dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=85057344171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057344171&partnerID=8YFLogxK

U2 - 10.1002/humu.23679

DO - 10.1002/humu.23679

M3 - Article

C2 - 30372562

AN - SCOPUS:85057344171

VL - 40

SP - 177

EP - 186

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 2

ER -